Clinical trials: PI3K and P110delta Hyperactivation Syndrome
PI3K and P110delta Hyperactivation Syndrome
CVL237 Tablets for APDS/PASLI
This study was designed to evaluate the efficacy and safety of CVL237 tablets in patients with APDS/PASLI (activated phosphoinositol 3-kinase δ syndrome /p110 delta-activated mutation leading to senescent T cells…
- Trial name
- NCT06293716
- Testing
- CVL237 tablets
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Convalife (Shanghai) Co., Ltd.